Panoptix Trifocal Lens in Post Refractive Myopic Laser Vision Correction Surgery

Last updated: March 15, 2021
Sponsor: Parkhurst NuVision Clinical Research LLC
Overall Status: Active - Recruiting

Phase

N/A

Condition

Eye Disease

Eye Disorders/infections

Vision Loss

Treatment

N/A

Clinical Study ID

NCT04698278
TFL210
  • Ages > 22
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The two main objectives of this study are to demonstrate safety and effectiveness of implanting the PanOptix Trifocal IOL in patients who have had previous myopic Lasik. The primary objectives to demonstrate clinical safety will be the quality of vision questionnaire (QUVID) which will demonstrate the patient's perception of halos, glares, and starbursts before and after the implantation of the trifocal IOL.

The primary objective to demonstrate clinical effectiveness will be done by measuring visual outcomes at distance, intermediate, and near. In addition, the patients will also fill out the spectacle independence questionnaire (IOLSAT Questionnaire) to determine their level of glasses independence postoperatively. In addition, at the conclusion of the study the patient will also fill out a patient satisfaction survey.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Adults, 22 years of age or older at the time of surgery, diagnosed with bilateralcataracts with planned cataract removal by phacoemulsification with a clear corneaincision
  2. Previous myopic Lasik with a well centered optical zone, corneal higher-orderaberrations less than 0.6 um for a 4 mm pupil (measured by iTrace), and a minimumkeratometric reading of 35.0 D.
  3. Able to comprehend and willing to sign informed consent and complete all requiredpostoperative follow-up procedures
  4. Best Corrected Distance Visual Acuity (BCDVA) projected to be 0.2 logMAR (MinimumAngle of Resolution) or better
  5. Calculated lens power within the available range
  6. Preoperative keratometric astigmatism at or less than 2.5 D in both operative eyes
  7. Clear intraocular media other than cataract in both eyes

Exclusion

Exclusion Criteria:

  1. Clinically significant corneal abnormalities including corneal dystrophy,irregularity, inflammation or edema.
  2. Previous intraocular surgery other than myopic Lasik
  3. History of or current retinal conditions or predisposition to retinal conditions
  4. Amblyopia
  5. Rubella, congenital, traumatic, or complicated cataracts
  6. History of or current anterior or posterior segment inflammation of any etiology
  7. Iris neovascularization
  8. Glaucoma (uncontrolled or controlled with medication)
  9. Optic nerve atrophy
  10. Subjects with diagnosed degenerative eye disorders
  11. Pregnancy or lactation
  12. Any disease or pathology, other than cataract, that is expected to reduce thepotential postoperative BCDVA to a level worse than 0.30 logMAR.

Study Design

Total Participants: 20
Study Start date:
March 08, 2021
Estimated Completion Date:
July 01, 2022

Study Description

Clinical Hypothesis:

The rate of bothersome visual symptom items (defined as a very or extremely bothersome visual symptom that impacts daily living under overall condition) for the patients who are post-refractive who receive a PanOptix Trifocal IOL at the time of cataract surgery will be assessed. The bothersome visual symptom items of interest are halos, glare, and starbursts. Patients will also be assessed on level of glasses independence with an assessment of both corrected and uncorrected distance, intermediate, and near vision. Lastly patient satisfaction score will also be determined.

OVERALL STUDY DESIGN This is a prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had prior myopic Lasik and will receive a PanOptix Trifocal IOL in both eyes at the time of cataract surgery. These patients will then be followed for up to 6-months to assess their refractive predictability, quality of vision, spectacle independence, and overall patient satisfaction.

Duration:

6 months; however, any subject that undergoes a lens repositioning procedure due to IOL misalignment, or reports "very" or "extreme" overall bother that impacts daily living for any of the 3 defined bothersome visual symptoms (halos, glare, or starbursts) at 6 months, will be followed through 1 year postoperatively.

Administration:

Surgeons will perform routine small-incision, femtosecond laser assisted, cataract surgery and use the Alcon-recommended implantation systems for lens implantation. Refractive target outcomes will be emmetropia for both eyes.

Visit Schedule:

Subjects will be bilaterally implanted; the second eye is to be implanted within approximately one month after the first-eye surgery.

All subjects will undergo a minimum of 10 visits:

  1. Preoperative for both eyes

  2. Surgical Procedure for each individual eye

  3. 1-day and 1-week visits for each eye

  4. 1-month, 3-month, and 6-month visits for both eyes together

  5. In addition, a 1-year postoperative visit will be required for subjects who undergo a lens repositioning procedure due to IOL misalignment at any time during the study, and for subjects who report "very" or "extreme" overall bother that impacts daily living for any of the 3 defined bothersome visual symptoms (halos, glare, or starbursts) at 6 months.

Connect with a study center

  • Parkhurst NuVision

    San Antonio, Texas 78229
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.